Finance

Lists
Q2 2026 earnings • released • EPS beat +12.79% • Revenue beat +0.73%
See results
PCRX:NASDAQ
Pacira Biosciences Inc
$25.02
-2.19%
(-0.56) 1D
$24.50
-2.08% (-0.52)
After hours
Closed: Aug 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PCRX...
Open
$25.67
High
$25.68
Low
$24.94
Mkt. cap
997.34M
Avg. vol.
609.39K
Volume
603.21K
P/E ratio
72.10
52-wk high
$27.66
52-wk low
$18.80
EPS
$0.35
Beta
0.27
Shares outstanding
39.86M
No. of employees
827
Open
$25.67
High
$25.68
Low
$24.94
Mkt. cap
997.34M
Avg. vol.
609.39K
Volume
603.21K
P/E ratio
72.10
52-wk high
$27.66
52-wk low
$18.80
EPS
$0.35
Beta
0.27
Shares outstanding
39.86M
No. of employees
827
News stories
From sources across the web
About Pacira Biosciences Inc
CEO-
Employees827
Founded2006
HeadquartersBrisbane, California, United States
SectorPharmaceutical industry
Websitepacira.com
Analyst ratings
Based on 4 analysts giving stock ratings to PCRX in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for PCRX in the last 3 months.
Highest
Current $25.02
$38.00 (+51.88%)
Average
$30.25 (+20.90%)
Lowest
$25.00 (-0.08%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$38.00
+51.9%
08/05/2026
Douglas Miehm
RBC Capital
Hold
Maintained
$25.00
-0.1%
08/05/2026
Serge Belanger
Needham
Buy
Maintained
$33.00
+31.9%
08/05/2026
Jenna Davidner
Barclays
Hold
Maintained
$25.00
-0.1%
05/14/2026
Les Sulewski
Truist Financial
Buy
Maintained
-
-
05/01/2026
Hardik Parikh
J.P. Morgan
Sell
Maintained
$23.00
-8.1%
03/20/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.73 / $0.65
+12.79%beat
Revenue / Est. (USD)
192.40M / 191.00M
+0.73%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
179.52M
196.87M
177.38M
192.40M
Cost of goods sold
34.28M
45.80M
36.41M
44.16M
Cost of revenue
34.28M
45.80M
36.41M
44.16M
Research and development expenses
25.97M
37.45M
28.07M
30.24M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
91.80M
101.61M
93.94M
91.81M
Operating expense
132.08M
153.38M
136.34M
136.37M
Total operating expenses
166.36M
199.18M
172.75M
180.54M
Operating income
13.15M
-2.31M
4.62M
11.86M
Other non operating income
-110.00K
-134.00K
-135.00K
-34.00K
EBT including unusual items
9.52M
571.00K
5.00M
2.56M
EBT excluding unusual items
17.30M
-4.04M
2.72M
10.15M
Income tax expense
4.09M
-1.07M
2.08M
-2.10M
Effective tax rate
42.97%
-186.69%
41.66%
-82.11%
Other operating expenses
-
-
-
-
Net income
5.43M
1.64M
2.92M
4.65M
Net profit margin
3.03%
0.83%
1.64%
2.42%
Earnings per share
0.70
0.57
0.60
0.73
Interest and investment income
8.53M
2.30M
1.93M
1.94M
Interest expense
-4.28M
-3.89M
-3.70M
-3.62M
Net interest expenses
4.26M
-1.60M
-1.77M
-1.68M
Depreciation and amortization charges
-
-
-
-
EBITDA
28.84M
24.53M
25.96M
33.82M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps